Related references
Note: Only part of the references are listed.Tuning Surface Charge and PEGylation of Biocompatible Polymers for Efficient Delivery of Nucleic Acid or Adenoviral Vector
Joung-Woo Choi et al.
BIOCONJUGATE CHEMISTRY (2015)
In vitro antitumor immune response induced by dendritic cells transduced with human livin α recombinant adenovirus
Junping Xie et al.
CELLULAR IMMUNOLOGY (2015)
CAV-2-why a canine virus is a neurobiologist's best friend
Felix Junyent et al.
CURRENT OPINION IN PHARMACOLOGY (2015)
Incorporation of Peptides Targeting EGFR and FGFR1 into the Adenoviral Fiber Knob Domain and Their Evaluation as Targeted Cancer Therapies
Hanni Uusi-Kerttula et al.
HUMAN GENE THERAPY (2015)
Increasing the density of nanomedicines improves their ultrasound-mediated delivery to tumours
Steven Mo et al.
JOURNAL OF CONTROLLED RELEASE (2015)
The future of immune checkpoint therapy
Padmanee Sharma et al.
SCIENCE (2015)
Manipulating Adenovirus Hexon Hypervariable Loops Dictates Immune Neutralisation and Coagulation Factor X-dependent Cell Interaction In Vitro and In Vivo
Jiangtao Ma et al.
PLOS PATHOGENS (2015)
Repeated intratumoral administration of ONCOS-102 leads to systemic antitumor CD8+ T-cell response and robust cellular and transcriptional immune activation at tumor site in a patient with ovarian cancer
L. Vassilev et al.
ONCOIMMUNOLOGY (2015)
Safety Profiles and Antitumor Efficacy of Oncolytic Adenovirus Coated with Bioreducible Polymer in the Treatment of a CAR Negative Tumor Model
Soo-Jung Jung et al.
BIOMACROMOLECULES (2015)
Incorporation of Porcine Adenovirus 4 Fiber Protein Enhances Infectivity of Adenovirus Vector on Dendritic Cells: Implications for Immune-Mediated Cancer Therapy
Ivy Wilkinson-Ryan et al.
PLOS ONE (2015)
Hexon Hypervariable Region-Modified Adenovirus Type 5 (Ad5) Vectors Display Reduced Hepatotoxicity but Induce T Lymphocyte Phenotypes Similar to Ad5 Vectors
Jeffrey E. Teigler et al.
CLINICAL AND VACCINE IMMUNOLOGY (2014)
Adenovirus Infections in Immunocompetent and Immunocompromised Patients
Thomas Lion
CLINICAL MICROBIOLOGY REVIEWS (2014)
Activity of a group B oncolytic adenovirus (ColoAd1) in whole human blood
Y. Di et al.
GENE THERAPY (2014)
Innate Immunity to Adenovirus
Rodinde Hendrickx et al.
HUMAN GENE THERAPY (2014)
ORCA-010, a Novel Potency-Enhanced Oncolytic Adenovirus, Exerts Strong Antitumor Activity in Preclinical Models
Wenliang Dong et al.
HUMAN GENE THERAPY (2014)
Adenovirus-Based Vaccines for Fighting Infectious Diseases and Cancer: Progress in the Field
Dragomira Majhen et al.
HUMAN GENE THERAPY (2014)
CD46-Mediated Transduction of a Species D Adenovirus Vaccine Improves Mucosal Vaccine Efficacy
Zenaido T. Camacho et al.
HUMAN GENE THERAPY (2014)
Circumventing Antivector Immunity: Potential Use of Nonhuman Adenoviral Vectors
Estrella Lopez-Gordo et al.
HUMAN GENE THERAPY (2014)
Lymphokine-activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in ascites
V. A. Jennings et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Formulation and in vitro and in vivo evaluation of a cationic emulsion as a vehicle for improving adenoviral gene transfer
Soo-Yeon Kim et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2014)
Bioreducible polymers for therapeutic gene delivery
Young Sook Lee et al.
JOURNAL OF CONTROLLED RELEASE (2014)
CTLA-4 and PD-L1 Checkpoint Blockade Enhances Oncolytic Measles Virus Therapy
Christine E. Engeland et al.
MOLECULAR THERAPY (2014)
The Use of Ovarian Cancer Cells from Patients Undergoing Surgery to Generate Primary Cultures Capable of Undergoing Functional Analysis
Rachel L. ODonnell et al.
PLOS ONE (2014)
Species D Human Adenovirus Type 9 Exhibits Better Virus-Spread Ability for Antitumor Efficacy among Alternative Serotypes
Junji Uchino et al.
PLOS ONE (2014)
Traceless Bioresponsive Shielding of Adenovirus Hexon with HPMA Copolymers Maintains Transduction Capacity In Vitro and In Vivo
Jan-Michael Prill et al.
PLOS ONE (2014)
Peptide-Based Technologies to Alter Adenoviral Vector Tropism: Ways and Means for Systemic Treatment of Cancer
Julia Reetz et al.
VIRUSES-BASEL (2014)
Armed therapeutic viruses - a disruptive therapy on the horizon of cancer immunotherapy
Maxine Bauzon et al.
FRONTIERS IN IMMUNOLOGY (2014)
Final planned overall survival (OS) from OPTiM, a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB/C/IV melanoma (NCT00769704)
Robert HI Andtbacka et al.
Journal for ImmunoTherapy of Cancer (2014)
Oncolytic viruses as anticancer vaccines
Norman Woller et al.
FRONTIERS IN ONCOLOGY (2014)
Chemotherapy and oncoyic virotherapy: advanced tactics in the war against cancer
Andrew Nguyen et al.
FRONTIERS IN ONCOLOGY (2014)
Going viral with cancer immunotherapy
Brian D. Lichty et al.
NATURE REVIEWS CANCER (2014)
Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma
Surasak Phuphanich et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF-Coding Oncolytic Adenovirus
Anna Kanerva et al.
CLINICAL CANCER RESEARCH (2013)
CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients
Patrick A. Ott et al.
CLINICAL CANCER RESEARCH (2013)
Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: A review
Kunn Hadinoto et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2013)
Pseudotyping the adenovirus serotype 5 capsid with both the fibre and penton of serotype 35 enhances vascular smooth muscle cell transduction
A. L. Parker et al.
GENE THERAPY (2013)
Assessment of a novel, capsid-modified adenovirus with an improved vascular gene transfer profile
Katie M. White et al.
JOURNAL OF CARDIOTHORACIC SURGERY (2013)
At the Bedside: CTLA-4-and PD-1-blocking antibodies in cancer immunotherapy
Margaret K. Callahan et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2013)
Enhanced Tumor Uptake and Penetration of Virotherapy Using Polymer Stealthing and Focused Ultrasound
Robert Carlisle et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
Alternative Serotype Adenovirus Vaccine Vectors Elicit Memory T Cells with Enhanced Anamnestic Capacity Compared to Ad5 Vectors
Pablo Penaloza-MacMaster et al.
JOURNAL OF VIROLOGY (2013)
Coagulation Factor Binding Orientation and Dimerization May Influence Infectivity of Adenovirus-Coagulation Factor Complexes
Eric E. Irons et al.
JOURNAL OF VIROLOGY (2013)
Oncolytic viruses as therapeutic cancer vaccines
David L. Bartlett et al.
MOLECULAR CANCER (2013)
Amgen announces oncolytic virus shrinks tumors
Cormac Sheridan
NATURE BIOTECHNOLOGY (2013)
Coagulation factor X shields adenovirus type 5 from attack by natural antibodies and complement
Zhili Xu et al.
NATURE MEDICINE (2013)
Development of a generic adenovirus delivery system based on structure-guided design of bispecific trimeric DARPin adapters
Birgit Dreier et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Molecular evolution of human adenoviruses
Christopher M. Robinson et al.
SCIENTIFIC REPORTS (2013)
Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research
Nuzhat Ahmed et al.
FRONTIERS IN ONCOLOGY (2013)
Evolution of oncolytic adenovirus for cancer treatment
Joung-Woo Choi et al.
ADVANCED DRUG DELIVERY REVIEWS (2012)
A hexon-specific PEGylated adenovirus vector utilizing blood coagulation factor X
Hayato Matsui et al.
BIOMATERIALS (2012)
Ultrasound-enhanced drug delivery for cancer
Steven Mo et al.
EXPERT OPINION ON DRUG DELIVERY (2012)
Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4
J. D. Dias et al.
GENE THERAPY (2012)
Biodistribution and inflammatory profiles of novel penton and hexon double-mutant serotype 5 adenoviruses
Angela C. Bradshaw et al.
JOURNAL OF CONTROLLED RELEASE (2012)
Identification of Adenovirus Serotype 5 Hexon Regions That Interact with Scavenger Receptors
Reeti Khare et al.
JOURNAL OF VIROLOGY (2012)
Adenovirus Serotype 5 Neutralizing Antibodies Target both Hexon and Fiber following Vaccination and Natural Infection
Ritu R. Bradley et al.
JOURNAL OF VIROLOGY (2012)
Adenovirus Serotype 5-Specific Neutralizing Antibodies Target Multiple Hexon Hypervariable Regions
Ritu R. Bradley et al.
JOURNAL OF VIROLOGY (2012)
Conserved Fiber-Penton Base Interaction Revealed by Nearly Atomic Resolution Cryo-Electron Microscopy of the Structure of Adenovirus Provides Insight into Receptor Interaction
Changchun Cao et al.
JOURNAL OF VIROLOGY (2012)
Adenovirus Serotype 26 Utilizes CD46 as a Primary Cellular Receptor and Only Transiently Activates T Lymphocytes following Vaccination of Rhesus Monkeys
Hualin Li et al.
JOURNAL OF VIROLOGY (2012)
Vaccination with Adenovirus Serotypes 35, 26, and 48 Elicits Higher Levels of Innate Cytokine Responses than Adenovirus Serotype 5 in Rhesus Monkeys
Jeffrey E. Teigler et al.
JOURNAL OF VIROLOGY (2012)
Ad5:Ad48 Hexon Hypervariable Region Substitutions Lead to Toxicity and Increased Inflammatory Responses Following Intravenous Delivery
Lynda Coughlan et al.
MOLECULAR THERAPY (2012)
Oncolytic virotherapy
Stephen J. Russell et al.
NATURE BIOTECHNOLOGY (2012)
Tumor Immunotherapy Directed at PD-1
Antoni Ribas
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Coagulation Factor X Activates Innate Immunity to Human Species C Adenovirus
Konstantin Doronin et al.
SCIENCE (2012)
Virus chimeras for gene therapy, vaccination, and oncolysis: adenoviruses and beyond
Johanna K. Kaufmann et al.
TRENDS IN MOLECULAR MEDICINE (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Hexon-specific PEGylated adenovirus vectors utilizing avidin-biotin interaction
Emi Suzuki-Kouyama et al.
BIOMATERIALS (2011)
Active targeting of RGD-conjugated bioreducible polymer for delivery of oncolytic adenovirus expressing shRNA against IL-8 mRNA
Jaesung Kim et al.
BIOMATERIALS (2011)
Translating Tumor Antigens into Cancer Vaccines
Luigi Buonaguro et al.
CLINICAL AND VACCINE IMMUNOLOGY (2011)
Species D Adenoviruses as Oncolytics against B-cell Cancers
Christopher Y. Chen et al.
CLINICAL CANCER RESEARCH (2011)
Combining conditionally replicating adenovirus-mediated gene therapy with chemotherapy: a novel antitumor approach
Guan Jiang et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Her2-specific Multivalent Adapters Confer Designed Tropism to Adenovirus for Gene Targeting
Birgit Dreier et al.
JOURNAL OF MOLECULAR BIOLOGY (2011)
Modifications of Adenovirus Hexon Allow for Either Hepatocyte Detargeting or Targeting With Potential Evasion From Kupffer Cells
Jan-Michael Prill et al.
MOLECULAR THERAPY (2011)
Integrated genomic analyses of ovarian carcinoma
D. Bell et al.
NATURE (2011)
Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14
Hongjie Wang et al.
NATURE MEDICINE (2011)
The GD1a glycan is a cellular receptor for adenoviruses causing epidemic keratoconjunctivitis
Emma C. Nilsson et al.
NATURE MEDICINE (2011)
Cell Entry and Trafficking of Human Adenovirus Bound to Blood Factor X Is Determined by the Fiber Serotype and Not Hexon: Heparan Sulfate Interaction
Stephanie Corjon et al.
PLOS ONE (2011)
International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations
Dan H. Barouch et al.
VACCINE (2011)
Optimized PEGylated Adenovirus Vector Reduces the Anti-vector Humoral Immune Response against Adenovirus and Induces a Therapeutic Effect against Metastatic Lung Cancer
Yusuke Eto et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2010)
The effect of surface modification of adenovirus with an arginine-grafted bioreducible polymer on transduction efficiency and immunogenicity in cancer gene therapy
Pyung-Hwan Kim et al.
BIOMATERIALS (2010)
Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors
Raul Alba et al.
BLOOD (2010)
Oncolytic Adenovirus ICOVIR-7 in Patients with Advanced and Refractory Solid Tumors
Petri Nokisalmi et al.
CLINICAL CANCER RESEARCH (2010)
OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma
Howard L. Kaufman et al.
FUTURE ONCOLOGY (2010)
Influence of chimeric human-bovine fibers on adenoviral uptake by liver cells and the antiviral immune response
S. Rogee et al.
GENE THERAPY (2010)
Retargeted adenoviral cancer gene therapy for tumour cells overexpressing epidermal growth factor receptor or urokinase-type plasminogen activator receptor
T. J. Harvey et al.
GENE THERAPY (2010)
Evaluation of cross-reactive cell-mediated immune responses among human, bovine and porcine adenoviruses
A. Sharma et al.
GENE THERAPY (2010)
Targeting Adenoviruses with Factor X-Single-Chain Antibody Fusion Proteins
Christopher Y. Chen et al.
HUMAN GENE THERAPY (2010)
Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary
Ashour Ahmed Ahmed et al.
JOURNAL OF PATHOLOGY (2010)
Differential Specificity and Immunogenicity of Adenovirus Type 5 Neutralizing Antibodies Elicited by Natural Infection or Immunization
Cheng Cheng et al.
JOURNAL OF VIROLOGY (2010)
Adenovirus-Based Vaccines: Comparison of Vectors from Three Species of Adenoviridae
H. Chen et al.
JOURNAL OF VIROLOGY (2010)
Potentiating Cancer Immunotherapy Using an Oncolytic Virus
Byram W. Bridle et al.
MOLECULAR THERAPY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: Correlates of high Ad5 titers and implications for potential HIV vaccine trials
T. Christopher Mast et al.
VACCINE (2010)
Tropism-Modification Strategies for Targeted Gene Delivery Using Adenoviral Vectors
Lynda Coughlan et al.
VIRUSES-BASEL (2010)
Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1
Robert C. Carlisle et al.
BLOOD (2009)
Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer
Raul Alba et al.
BLOOD (2009)
Chemical Modification with High Molecular Weight Polyethylene Glycol Reduces Transduction of Hepatocytes and Increases Efficacy of Intravenously Delivered Oncolytic Adenovirus
Konstantin Doronin et al.
HUMAN GENE THERAPY (2009)
Virus Binding to a Plasma Membrane Receptor Triggers Interleukin-1α-Mediated Proinflammatory Macrophage Response In Vivo
Nelson C. Di Paolo et al.
IMMUNITY (2009)
Adenovirus serotype 5 infects human dendritic cells via a coxsackievirus-adenovirus receptor-independent receptor pathway mediated by lactoferrin and DC-SIGN
William C. Adams et al.
JOURNAL OF GENERAL VIROLOGY (2009)
Adenoviruses: update on structure and function
W. C. Russell
JOURNAL OF GENERAL VIROLOGY (2009)
Effect of Neutralizing Sera on Factor X-Mediated Adenovirus Serotype 5 Gene Transfer
Alan L. Parker et al.
JOURNAL OF VIROLOGY (2009)
The Cell Adhesion Molecule CAR'' and Sialic Acid on Human Erythrocytes Influence Adenovirus In Vivo Biodistribution
Elena Seiradake et al.
PLOS PATHOGENS (2009)
Bioselection of a Gain of Function Mutation that Enhances Adenovirus 5 Release and Improves Its Antitumoral Potency
Alena Gros et al.
CANCER RESEARCH (2008)
Adenovirus serotype 5 hexon mediates liver gene transfer
Simon N. Waddington et al.
CELL (2008)
Changing the adenovirus fiber for retaining gene delivery efficacy in the presence of neutralizing antibodies
M. Sarkioja et al.
GENE THERAPY (2008)
Complex interactions with several arms of the complement system dictate innate and humoral immunity to adenoviral vectors
D. M. Appledorn et al.
GENE THERAPY (2008)
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial
Susan P. Buchbinder et al.
LANCET (2008)
Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial
Byeong-Ho Park et al.
LANCET ONCOLOGY (2008)
Modification of adenovirus gene transfer vectors with synthetic polymers: A scientific review and technical guide
Florian Kreppel et al.
MOLECULAR THERAPY (2008)
Directed Evolution Generates a Novel Oncolytic Virus for the Treatment of Colon Cancer
Irene Kuhn et al.
PLOS ONE (2008)
Adenovirus serotype 5 hexon is critical for virus infection of heptocytes in vivo
O. Kalyuzhniy et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Adenovirus vector induced innate immune responses: Impact upon efficacy and toxicity in gene therapy and vaccine applications
Zachary C. Hartman et al.
VIRUS RESEARCH (2008)
HIV vaccine development in the aftermath of the STEP study:: Re-focus on occult HIV infection?
Klaus Ueberla
PLOS PATHOGENS (2008)
Modification of adenovirus capsid with a designed protein ligand yields a gene vector targeted to a major molecular marker of cancer
Natalya Belousova et al.
JOURNAL OF VIROLOGY (2008)
Identification of CD46 binding sites within the adenovirus serotype 35 fiber knob
Hongjie Wang et al.
JOURNAL OF VIROLOGY (2007)
An oncolytic adenovirus redirected with a tumor-specific T-Cell receptor
Zsolt Sebestyen et al.
CANCER RESEARCH (2007)
Fiber shaft-chimeric adenovirus vectors lacking the KKTK motif efficiently infect liver cells in vivo
Nelson C. Di Paolo et al.
JOURNAL OF VIROLOGY (2007)
Systemic toxicity-efficacy profile of ICOVIR-5, a potent and selective oncolytic adenovirus based on the pRB pathway
Manel Cascallo et al.
MOLECULAR THERAPY (2007)
Targeting of adenovirus serotype 5 (Ad5) and 5/47 pseudotyped vectors in vivo: Fundamental involvement of coagulation factors and redundancy of CAR binding by Ad5
Simon N. Waddington et al.
JOURNAL OF VIROLOGY (2007)
PD-1 and PD-1 ligands: from discovery to clinical application
Taku Okazaki et al.
INTERNATIONAL IMMUNOLOGY (2007)
Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D
Peter Abbink et al.
JOURNAL OF VIROLOGY (2007)
A conditionally replicating adenovirus with strict selectivity in killing cells expressing epidermal growth factor receptor
Jan E. Carette et al.
VIROLOGY (2007)
Adenovirus 5 fibers mutated at the putative HSPG-binding site show restricted retargeting with targeting peptides in the HI loop
Angelika B. Kritz et al.
MOLECULAR THERAPY (2007)
Adenovirus vector delivery stimulates natural killer cell recognition
Peter Tomasec et al.
JOURNAL OF GENERAL VIROLOGY (2007)
Influence of coagulation factor zymogens on the infectivity of adenoviruses pseudotyped with fibers from subgroup D
Alan L. Parker et al.
JOURNAL OF VIROLOGY (2007)
Adenovirus-induced thrombocytopenia: the role of von Willebrand factor and P-selectin in mediating accelerated platelet clearance
Maha Othman et al.
BLOOD (2007)
Decreased immune reactivity towards a knobless, affibody-targeted adenovirus type 5 vector
S. Myhre et al.
GENE THERAPY (2007)
The CD4(+) T-cell response to adenovirus is focused against conserved residues within the hexon protein
David Onion et al.
JOURNAL OF GENERAL VIROLOGY (2007)
Clinical trials with oncolytic adenovirus in China
Wang Yu et al.
CURRENT CANCER DRUG TARGETS (2007)
Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes
Alan L. Parker et al.
BLOOD (2006)
Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa
Anna R. Thorner et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2006)
Role of the putative heparan sulfate glycosaminoglycan-binding site of the adenovirus type 5 fiber shaft on liver detargeting and knob-mediated retargeting
Neus Bayo-Puxan et al.
JOURNAL OF GENERAL VIROLOGY (2006)
CTLA-4 overexpression inhibits T cell responses through a CD28-B7-dependent mechanism
John J. Engelhardt et al.
JOURNAL OF IMMUNOLOGY (2006)
A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer
Eric J. Small et al.
MOLECULAR THERAPY (2006)
Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity
DM Roberts et al.
NATURE (2006)
The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: Correlation with important high-risk prognostic factors
Hazem Ghebeh et al.
NEOPLASIA (2006)
Primary culture of ovarian surface epithelial cells and ascites-derived ovarian cancer cells from patients
Trevor G. Shepherd et al.
NATURE PROTOCOLS (2006)
Phylogenetic analysis of the main neutralization and hemagglutination determinants of all human adenovirus prototypes as a basis for molecular classification and taxonomy
I Madisch et al.
JOURNAL OF VIROLOGY (2005)
Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein
SM Sumida et al.
JOURNAL OF IMMUNOLOGY (2005)
Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity
DM Shayakhmetov et al.
JOURNAL OF VIROLOGY (2005)
CAR: A virus receptor within the tight junction
CB Coyne et al.
ADVANCED DRUG DELIVERY REVIEWS (2005)
Enhanced gene transfer activity of peptide-targeted gene-delivery vectors
AL Parker et al.
JOURNAL OF DRUG TARGETING (2005)
Adenoviruses for treatment of cancer
A Kanerva et al.
ANNALS OF MEDICINE (2005)
The structure of the human adenovirus 2 penton
C Zubieta et al.
MOLECULAR CELL (2005)
Deletion of penton RGD motifs affects the efficiency of both the internalization and the endosorne escape of viral particles containing adenovirus serotype 5 or 35 fiber knobs
DM Shayakhmetov et al.
JOURNAL OF VIROLOGY (2005)
Influence of fiber detargeting on adenovirus-mediated innate and adaptive immune activation
JW Schoggins et al.
JOURNAL OF VIROLOGY (2005)
Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors
SM Sumida et al.
JOURNAL OF VIROLOGY (2004)
Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States
E Nwanegbo et al.
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY (2004)
Use of replicating oncolytic adenoviruses in combination therapy for cancer
RL Chu et al.
CLINICAL CANCER RESEARCH (2004)
An adenoviral type 5 vector carrying a type 35 fiber as a vaccine vehicle:: DC targeting, cross neutralization, and immunogenicity
OJAE Ophorst et al.
VACCINE (2004)
Crystal structure of species D adenovirus fiber knobs and their sialic acid binding sites
WP Burmeister et al.
JOURNAL OF VIROLOGY (2004)
An adenovirus vector with a chimeric fiber derived from canine adenovirus type 2 displays novel tropism
JN Glasgow et al.
VIROLOGY (2004)
Postentry neutralization of adenovirus type 5 by an antihexon antibody
R Varghese et al.
JOURNAL OF VIROLOGY (2004)
Adenoviral serotype 5 vectors pseudotyped with fibers from subgroup D show modified tropism in vitro and in vivo
L Denby et al.
HUMAN GENE THERAPY (2004)
Neutralizing antibody evasion ability of adenovirus vector induced by the bioconjugation of methoxypolyethylene glycol succinimidyl propionate (MPEG-SPA)
Y Eto et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2004)
Porcine adenoviral vectors evade preexisting humoral immunity to adenoviruses and efficiently infect both human and murine cells in culture
DS Bangari et al.
VIRUS RESEARCH (2004)
An adenoviral vector cancer vaccine that delivers a tumor-associated antigen/CD40-ligand fusion protein to dendritic cells
LX Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Identification of adenovirus (Ad) penton base neutralizing epitopes by use of sera from patients who had received conditionally replicative ad (Addl1520) for treatment of liver tumors
SS Hong et al.
JOURNAL OF VIROLOGY (2003)
Flexibility of the adenovirus fiber is required for efficient receptor interaction
E Wu et al.
JOURNAL OF VIROLOGY (2003)
Immunity to adenovirus and adeno-associated viral vectors: implications for gene therapy
K Jooss et al.
GENE THERAPY (2003)
Adenovirus serotype 5 fiber shaft influences in vivo gene transfer in mice
TAG Smith et al.
HUMAN GENE THERAPY (2003)
A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy
DE Post et al.
ONCOGENE (2003)
Conditionally replicative adenovirus expressing a targeting adapter molecule exhibits enhanced oncolytic potency on CAR-deficient tumors
VW van Beusechem et al.
GENE THERAPY (2003)
Intravascular adenoviral agents in cancer patients: Lessons from clinical trials
T Reid et al.
CANCER GENE THERAPY (2002)
Adenovirus fiber disrupts CAR-mediated intercellular adhesion allowing virus escape
RW Walters et al.
CELL (2002)
Integrin αv and coxsackie adenovirus receptor expression in clinical bladder cancer
MD Sachs et al.
UROLOGY (2002)
The therapeutic efficacy of adenoviral vectors for cancer gene therapy is limited by a low level of primary adenovirus receptors on tumour cells
M Kim et al.
EUROPEAN JOURNAL OF CANCER (2002)
Serum and ascites neutralizing antibodies in ovarian cancer patients treated with intraperitoneal adenoviral gene therapy
A Hemminki et al.
HUMAN GENE THERAPY (2002)
The adenovirus capsid protein hexon contains a highly conserved human CD4+ T-cell epitope
M Olive et al.
HUMAN GENE THERAPY (2002)
In vivo hepatic adenoviral gene delivery occurs independently of the coxsackievirus-adenovirus receptor
T Smith et al.
MOLECULAR THERAPY (2002)
Enhancement of the adenoviral sensitivity of human ovarian cancer cells by transient expression of coxsackievirus and adenovirus receptor (CAR)
JS Kim et al.
GYNECOLOGIC ONCOLOGY (2002)
Complement activation by recombinant adenoviruses
G Cichon et al.
GENE THERAPY (2001)
The role of adenovirus E4orf4 protein in viral replication and cell killing
PE Branton et al.
ONCOGENE (2001)
Genetic retargeting of adenovirus: Novel strategy employing deknobbing of the fiber
MK Magnusson et al.
JOURNAL OF VIROLOGY (2001)
Targeting of adenovirus to endothelial cells by a bispecific single-chain diabody directed against the adenovirus fiber knob domain and human endoglin (CD105)
DM Nettelbeck et al.
MOLECULAR THERAPY (2001)
Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity
J Nemunaitis et al.
GENE THERAPY (2001)
Coxsackievirus-adenovirus receptor expression in ovarian cancer cell lines is associated with increased adenovirus transduction efficiency and transgene expression
ZB You et al.
CANCER GENE THERAPY (2001)
Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies
KD Fisher et al.
GENE THERAPY (2001)
Using a tropism-modified adenoviral vector to circumvent inhibitory factors in ascites fluid
JL Blackwell et al.
HUMAN GENE THERAPY (2000)
Ectodomain of coxsackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus targeting to epidermal growth factor receptor-positive cells
I Dmitriev et al.
JOURNAL OF VIROLOGY (2000)
Circumvention of vector-specific neutralizing antibody response by alternating use of human and non-human adenoviruses: Implications in gene therapy
S Moffatt et al.
VIROLOGY (2000)
Neutralisation of adenovirus infectivity by ascitic fluid from ovarian cancer patients
Y Stallwood et al.
GENE THERAPY (2000)
A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo
J Fueyo et al.
ONCOGENE (2000)
Identification of contact residues and definition of the CAR-binding site of adenovirus type 5 fiber protein
I Kirby et al.
JOURNAL OF VIROLOGY (2000)
Share Paper
